Index 



307 



Prednisone therapy (Continued) 



in lymphatic leukemia, chronic. 216. 219 

 in lymphoproliferative disorders, 258 

 in lymphosarcoma, 231 



in pruritus of lymphocytic lymphomas, 250 

 Premitotic synthesis of DNA, 35 

 Preplasma cells in cell transfer studies. 87, 94 

 Price, C. H. G.. 132 



Prognosis of lymphocytic lymphomas, 202-253 

 Proliferation, of fibroblasts, enzyme activity in. 

 197. 198 

 of lymphoid tissues, 257-259 



in leukemia. 179 

 transitions in myeloproliferative disorders, 

 181 

 Prolymphoc) tes, 277-279 

 in cell transfer studies, S7 

 in hyperplastic lymph node. 15 

 in lvmph nodes, 16 

 in marrow, 16 



maturation of, and Cortisol action, 12(1 

 mitosis in, in lymphocytosis of infancy, 17 

 reticular, lymphocytokaryorrhectic hormones 



affecting, 119 

 in thymus, 16 

 Proplasmacytes, 283, 284 



Proteins, abnormal, in lymphocytic lymphomas, 

 250, 252 

 and amino acids, 37 

 as antigen for in vitro incubation with 



lymph node cells, 106 

 diets deficient in, serous fat atrophy from, 



245 

 immune response to, 83, 104 

 in lymphocytes, after adrenalectomy. 111 

 secretions in plasma cell, 285 

 synthesis of, 120 

 Pruritus in lymphocytic lymphomas, 251 



prednisone in, 250 

 Pseudoesinophils, in inflammations, 79 

 Pseudomononucleosis, 154 

 Puck. T. T„ 138 

 Purpura, in lymphatic leukemia, chronic, 214 



in lymphoproliferative disorders, 257 

 Pyknosis, in lymphocytes, after adrenalectomy, 

 112 

 adrenocortical hormones affecting, 119 

 radiation affecting, 126, 130, 132, 134 

 in plasma cell, 284 

 Pvronine stains of cells, 35 



in grafts, 101, 102 

 Pyroninophilic granules of lymphoid cells, 

 after grafting, 102 



Rabbit, bacilli injections, and appearance of 

 agglutinins, 104, 105 

 cell transfer studies in, 83 

 antibody formation after, 104 

 contact with antigen in yitro, 105 



Rabbit, cell transfer studies in (Continued) 

 cytologic composition of lymph node cells. 

 103 

 draining lymph nodes at graft sites, 102 

 hematopoiesis in, 23 

 immune responses in. 89 

 lymphocytes in homografts, 101 

 lymphoid cells of, 4 

 migration and hypertrophy of lymphocytes 



in. 79 

 radiation of, debris-laden cells after. 130 

 lymph nodes after, 130 

 lymphocyte count in, 132, 133 

 lymphocytes after, in vitro studies, 125 

 lymphopenia after, 140 

 recovery after, 139, 140 

 transfer of transplantation immunity, 107 

 transplants of tissue fragments, 105 

 Radiation, and alkaline phosphatase nc ti\ ii \ . 

 42 

 in cell transfer studies, 83, 90, 93. 104. 105 

 cellular reaction in grafts after, 100 

 and esterase activity, 44 

 in follicular lymphoma, 207 

 in Hodgkin's disease, 243, 246 

 granuloma, 236, 239 

 paragranuloma, 234 

 initial destructive stage, 130-135 

 layvs of Bergonie and Tribondeau, 131. 219 

 in lymphatic leukemia, chronic, 212, 216, 



223 

 lymphocytes after. 125-141 



blood lymphocytes, 132, 135, 139 

 lymphocytosis from chronic exposure, 149 

 lymphoid tissue, 130-132, 136-138, 139 

 in lymphosarcoma, 228, 231 

 morphologic changes, chronic, 138 

 recovery stage, 139-140 



abortiye, 135 

 species effect, 140 

 sulfhydryl groups after, 38 

 survival time of cells, 128 

 total body irradiation, lethal, 131 



serous fat atrophy from, 245 

 and transplants of tissue fragments, 105 

 in yitro studies, 125-129 

 in vivo studies, 129-141 

 Radici, G., 102 



Radioautography of cells, 17, 18 

 Radioiodine, in proteins, immune response to, 

 104 

 ref tactile cytoplasmic granules after, 138 

 Radiophosphorus, in lymphatic leukemia, 

 chronic, 216, 224 

 in lymphosarcoma, 228 

 Radiosensitivity of lymphocytes, 128 

 Radiosulfur, in antibody synthesis studies, 93 



